文献速递白血病MDS 与骨髓增殖性肿瘤

全基因组筛选揭示细胞周期控制是SRSF2P95H突变的合成致死通路

Genome-wide screening identifies cell-cycle control as a synthetic lethal pathway with SRSF2P95H mutation.
PubMed 文献 · Blood Adv · 2022-01-01

本研究通过数据挖掘和功能筛选探索SRSF2P95H突变的合成致死遗传相互作用。分析人鼠SRSF2P95H突变样本的错剪接事件发现细胞周期和DNA修复通路富集;全基因组CRISPR功能缺失筛选证实细胞周期和DNA损伤应答通路为top合成致死通路,CDK6抑制剂palbociclib对SRSF2P95H细胞有优先敏感性。

要点

  • 细胞周期和DNA损伤应答通路是SRSF2P95H突变的合成致死通路
  • CDK6抑制剂palbociclib在SRSF2P95H细胞系和原代细胞中显示优先敏感性
  • palbociclib可能成为靶向SRSF2突变癌症的替代治疗选择

核心结论

  • 细胞周期和DNA损伤应答通路是Srsf2P95H/+细胞生存所必需,palbociclib可能成为靶向SRSF2突变癌症的替代治疗选择。

研究设计与样本

  • 结合数据挖掘和功能筛选,分析人鼠SRSF2P95H突变样本的错剪接事件,并进行全基因组CRISPR功能缺失筛选。

主要发现

  • 保守错剪接转录本集中细胞周期和DNA修复通路过代表。
  • 全基因组CRISPR筛选显示细胞周期和DNA损伤应答通路为top合成致死通路。
  • 靶向Cdk6的sgRNA丢失,palbociclib在Srsf2P95H/+细胞系和原代lin-cKIT+Sca-1+细胞中较野生型对照显示优先敏感性。

临床怎么用

  • palbociclib可考虑作为SRSF2突变髓系肿瘤的潜在治疗选择,需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current strategies to target RNA splicing mutant myeloid cancers proposes targeting the remaining splicing apparatus. This approach has only been modestly sensitizing and is also toxic to non-mutant-bearing wild-type cells. To explore potentially exploitable genetic interactions with spliceosome mutations, we combined data mining and functional screening for synthetic lethal interactions with an Srsf2P95H/+ mutation. Analysis of missplicing events in a series of both human and murine SRSF2P95H mutant samples across multiple myeloid diseases (acute myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia) was performed to identify conserved missplicing events. From this analysis, we identified that the cell-cycle and DNA repair pathways were overrepresented within the conserved misspliced transcript sets. In parallel, to functionally define pathways essential for survival and proliferation of Srsf2P95H/+ cells, we performed a genome-wide Clustered regularly interspaced short palindromic repeat loss-of-function screen using Hoxb8 immortalized R26-CreERki/+Srsf2P95H/+ and R26-CreERki/+Srsf2+/+ cell lines. We assessed loss of single guide RNA representation at 3 timepoints: immediately after Srsf2P95H/+ activation, and at 1 week and 2 weeks after Srsf2P95H/+ mutation. Pathway analysis demonstrated that the cell-cycle and DNA damage response pathways were among the top synthetic lethal pathways with Srsf2P95H/+ mutation. Based on the loss of guide RNAs targeting Cdk6, we identified that palbociclib, a CDK6 inhibitor, showed preferential sensitivity in Srsf2P95H/+ cell lines and in primary nonimmortalized lin-cKIT+Sca-1+ cells compared with wild-type controls. Our data strongly suggest that the cell-cycle and DNA damage response pathways are required for Srsf2P95H/+ cell survival, and that palbociclib could be an alternative therapeutic option for targeting SRSF2 mutant cancers.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Xu JJ, Chalk AM, Nikolic I, et al. Genome-wide screening identifies cell-cycle control as a synthetic lethal pathway with SRSF2P95H mutation. Blood Adv. 2022. PMID: 34464972. doi:10.1182/bloodadvances.2021004571

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。